COMMUNIQUÉS West-GlobeNewswire

Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
25/03/2026
Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments [...]
Zelluna ASA [ZLNA]: Annual Report 2025
25/03/2026
Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of [...]
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
25/03/2026
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
MitoSynergy Introduces BioCopper1® - A Clinically Proven Nutraceutical Designed for Mitochondrial Performance
25/03/2026
Scottsdale, AZ, March 24, 2026 (GLOBE NEWSWIRE) -- MitoSynergy , a science-driven wellness company focused on cellular and mitochondrial health, today announced the introduction of an improved BioCopper1®, a patented [...]
DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris
24/03/2026
Châtillon, France, le 24 mars (22 :30 CET) 2026 DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris Les modifications sont entrées en vigueur le lundi 23 mars [...]
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
24/03/2026
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total [...]
BioCardia Reports 2025 Business Highlights and Financial Results
24/03/2026
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
24/03/2026
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
24/03/2026
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets [...]
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
24/03/2026
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN [...]
BioSyent Announces Grant of Restricted Share Units
24/03/2026
MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Share Units “RSUs” to [...]
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal [...]
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
24/03/2026
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “ [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
24/03/2026
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]
Glass House Brands Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in Glass House history [...]
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
24/03/2026
CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
24/03/2026
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports [...]
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
24/03/2026
Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026 Completed 52-week follow-up from Phase II trial [...]

Pages